8-K: Evofem Biosciences Announces Amended Merger Agreement with Aditxt, Inc.

Evofem Biosciences has entered into an amended merger agreement with Aditxt, Inc., outlining the terms of their business combination.

Summary

• Evofem Biosciences, Inc. has entered into an Amended and Restated Merger Agreement with Aditxt, Inc. and Adifem, Inc., a subsidiary of Aditxt.
• This agreement amends and restates a previous merger agreement from December 2023, with several amendments made in early 2024.
• The merger consideration includes a cash payment of $1.8 million, less a deduction based on dissenting shares, and the conversion of Evofem's Series E-1 Preferred Stock into Aditxt Preferred Stock on a one-to-one basis.
• Convertible note holders will exchange their notes for up to 88,161 shares of Aditxt Preferred Stock.
• Evofem stock options will be cancelled without any compensation.
• Aditxt has agreed to purchase additional shares of Evofem's Series F-1 Preferred Stock in tranches, totaling $4 million, with the final purchase contingent on Aditxt raising at least $20 million in a public offering.
• The merger is subject to several conditions, including shareholder approvals, regulatory clearances, and Aditxt securing sufficient financing.
• Evofem's board has approved the merger and recommends that shareholders vote in favor of it.
• The agreement allows Evofem to consider superior offers, subject to a notice period and negotiation with Aditxt.

Sentiment

Score: 7

Explanation: The document outlines a merger agreement, which is generally a positive development for both companies. However, the deal is complex and subject to several conditions, which introduces some uncertainty. The sentiment is therefore moderately positive.

Positives

• The merger provides a clear path for Evofem to combine with Aditxt.
• The agreement includes a cash component of $1.8 million, providing some immediate value to shareholders.
• Preferred shareholders will receive shares in the merged entity.
• Aditxt's commitment to purchase additional preferred stock provides Evofem with additional capital.
• The agreement allows Evofem to consider superior offers, potentially increasing shareholder value.

Negatives

• Evofem stock options will be cancelled without any compensation.
• The cash consideration is reduced by the value of any dissenting shares.
• The final $2 million purchase of F-1 Preferred Stock is contingent on Aditxt raising at least $20 million in a public offering, which is not guaranteed.
• The merger is subject to numerous conditions, which could delay or prevent its completion.

Risks

• The merger is subject to shareholder and regulatory approvals, which may not be obtained.
• Aditxt may not secure sufficient financing to complete the merger.
• The merger could be delayed or terminated if a superior offer is made for Evofem.
• The value of Aditxt stock may fluctuate, impacting the value of the merger consideration.
• There is a risk that the merger may not deliver the expected benefits to shareholders.

Future Outlook

The document outlines the steps and conditions required for the merger to be completed, including shareholder approvals, regulatory clearances, and Aditxt securing sufficient financing. The merger is expected to close by September 30, 2024, if all conditions are met.

Management Comments

• The Company Board has determined that the A&R Merger Agreement and the transactions contemplated thereby, including the Merger, are advisable and in the best interests of the Company and its stockholders.
• The Company Board has directed that the adoption of the A&R Merger Agreement be submitted to a vote at a meeting of the Company stockholders.
• The Company Board has resolved to recommend that the Company stockholders adopt the Merger Agreement.

Industry Context

This merger is occurring in the biotechnology/pharmaceutical industry, where consolidation and strategic partnerships are common. The merger could allow Evofem to leverage Aditxt's resources and expertise, while Aditxt could benefit from Evofem's product pipeline and market presence.

Comparison to Industry Standards

• Merger agreements in the biotech industry often involve complex deal structures, including cash, stock, and contingent payments, similar to this agreement.
• The use of preferred stock as part of the consideration is common in mergers involving companies with complex capital structures.
• Contingent payments based on future financing or product milestones are also typical in this sector.
• The inclusion of a 'go-shop' provision, allowing Evofem to consider superior offers, is a standard practice to ensure the best outcome for shareholders.
• The conditions for closing, such as shareholder approvals and financing, are consistent with industry norms.

Stakeholder Impact

• Shareholders of Evofem will receive cash and/or stock in Aditxt.
• Convertible note holders will exchange their notes for Aditxt stock.
• Evofem employees may be offered employment by Aditxt.
• The merger could impact the future direction of Evofem's products and services.

Next Steps

• Evofem will file a proxy statement with the SEC.
• Evofem will hold a shareholder meeting to vote on the merger.
• Aditxt will seek shareholder approval for the stock issuance.
• Aditxt will work to secure the necessary financing.
• The parties will work to satisfy all closing conditions.

Key Dates

Keywords

merger, acquisition, Evofem Biosciences, Aditxt, preferred stock, convertible notes, shareholder approval, financing, biotech, pharmaceutical